Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Sanofi, GSK to supply up to 60 million doses of COVID-19 vaccine to UK

By Sean Whooley | August 3, 2020

Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) announced that they reached an agreement with the UK government to supply up to 60 million doses of a COVID-19 vaccine.

Subject to a final contract, the UK government will receive the doses of a vaccine candidate developed by the two companies in partnership and based on the recombinant protein-based technology Sanofi used to produce an influenza vaccine, along with GSK’s pandemic adjuvant technology, according to a news release.

Sanofi expects a Phase 1/2 study for the vaccine candidate to begin in September, followed by a Phase 3 study by the end of 2020. If the sudies report positive data, regulatory approval could be garnered by the first half of 2021, while the two companies are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall.

“With our partner GSK, we are pleased to cooperate with the UK government as well as several other countries and global organizations as part of our ongoing efforts to develop a safe and effective vaccine and make it available as quickly as possible,” Sanofi Pasteur EVP & global head Thomas Triomphe said in the release. “We greatly appreciate the UK government’s support of this shared vision.”

Last week, the two companies announced that they received a $1.2 billion award from the U.S. government for the development of the vaccine. The award was the largest among the more than $8 billion that the federal government, under its Operation Warp Speed program, has pledged to different companies for COVID-19 vaccine development.

“We believe that this adjuvanted vaccine candidate has the potential to play a significant role in overcoming the COVID-19 pandemic, both in the UK and around the world,” GSK vaccines president Roger Connor added. “We thank the UK government for confirmation of purchasing intent, which supports the significant investment we are already making as a company to scale up development and production of this vaccine.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Data sciencea
Q&A: Keys to unlock data science potential for drug discovery
Emulate Bio
Organ-chips could streamline drug development, but hurdles remain
Novavax
Novavax stock dips 14% on the heels of Q4 announcement

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards